伏立康唑治疗肺部侵袭性真菌感染84例疗效及安全性评价

摘要

Objective To evaluate the effect and safety of voriconazole in treating the patients with invasive pulmonary fungal infection. Methods 78 patients with invasive fungal infections in the respiratory department of our hospital were selected and given the voricona-zole treatment. The symptoms and signs, laboratory and microbial indicators, curative effect, microbial clearance rate and safety of the drug were analyzed and evaluated. Results In the patients with evaluable effect, the mycological clearance rate, curative rate and total effec-tive rate were 83. 33%, 38. 46% and 92. 31%, respectively; The adverse reactions included 16 cases ( 20. 51% ) of insomnia, 3 cases ( 3. 85%) of depression, 6 cases ( 7. 69%) of vertigo, 4 cases ( 5. 13%) of aminotransferase increase, 2 cases ( 2. 56%) of blood pres-sure elevation and 1 case ( 1. 28% ) of chemosis and were improved by the symptomatic treatment. Conclusion Voriconazole is a new type antifungal drug. As the optimal clinical drug for treating pulmonary invasive fungal infection, voriconazole has the characteristics of high efficacy and safety and is worthy of being clinically promoted.%目的：观察伏立康唑治疗肺部侵袭性真菌感染的疗效与安全性。方法选取西南医院呼吸内科侵袭性真菌感染患者78例，均给予伏立康唑治疗，观察症状体征、实验室及微生物指标，并对该药疗效、细菌清除率及安全性进行分析评价。结果可评价疗效的患者中，伏立康唑对真菌感染的清除率为83.33%，治愈率为38.46%，总有效率为92.31%；不良反应有失眠16例（20.51%），抑郁3例（3.85%），眩晕6例（7.69%），转氨酶升高4例（5.13%），恶心呕吐4例(5.13%)，血压升高2例（2.56%），球结膜水肿1例（1.28%），经对症治疗后均好转。结论伏立康唑为新型抗真菌药物，是目前治疗肺部侵袭性真菌感染的较佳临床药物，具有疗效高、安全等特点，值得临床推广。